CHMP recommends Keppra for infants
This article was originally published in Scrip
Executive Summary
The EU'S CHMP has recommended a label extension for UCB's antiepileptic Keppra (levetiracetam) to include the adjunctive treatment of partial-onset seizures in paediatric patients aged from one month to four years.